Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Launches New Women's Health Group (Law360)

Related Content

HHS-OCR Publishes Final HIPAA Privacy Rule Expanding Reproductive Health Care Privacy and Further Supporting Patient Confidentiality

Alabama IVF Clinics: Potential Implications of the LePage Case

A Tale of Two Lawsuits: Federal Court in Texas Suspends FDA Approval of Medication Abortion Drug Mifepristone Nationwide, While Federal Court in Washington Orders FDA to Not Alter Availability of Mifepristone in 17 States and D.C.

Texas Sues to Challenge Federal Guidance Asserting that Refusal to Fill Prescriptions for Certain Drugs Used to Manage Reproductive Health and Other Conditions May Violate Anti-Discrimination Laws

Implications of Abortion Laws for Fertility Services

Healthcare in a Post-Roe World

The Potential Impact of State Abortion Laws on Reproductive Health Apps

Taking Security Interests in Human Reproductive Tissue: Clarifying Lender Options under Federal and State Law

FemHealth Ventures Closes $32 Million Fund for Women’s Health Investments (The Wall Street Journal)

Texas Abortion Drug Ruling Could Create ‘Slippery Slope’ for FDA Approvals, Drug Research and Patients, Experts Say (CNN)

6 Burning Questions About How the FDA Will Handle Conflicting Abortion Pill Decisions (STAT)

Federal Judge Rules to Freeze Use of Abortion Pill Nationwide (Axios)

Analysis: Texas Abortion Pill Ruling Could Disrupt U.S. Drug Oversight (Reuters)

Abortion Pill Ruling Looms Over FDA's Drug Approval Process (Axios)

Abortion Pill Court Docket Delay Concerns Legal Advocates (Bloomberg Law)

Women, Influence & Power in Law UK Awards Name Ariel White-Tsimikalis Mentor of the Year

Women's Health & Wellness

Private Equity

Healthcare

Technology

Life Sciences

Real Estate

Financial Services

Medtech

Complex Litigation & Dispute Resolution

Litigation